​

Olema Pharmaceuticals (OLMA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

OLMA Stock Forecast

Olema Pharmaceuticals (OLMA) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $28.33, with a high of $35.00 and a low of $20.00. This represents a 341.97% increase from the last price of $6.41.

$5 $11 $17 $23 $29 $35 High: $35 Avg: $28.33 Low: $20 Last Closed Price: $6.41

OLMA Stock Rating

Olema Pharmaceuticals stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 9 Strong Sell Sell Hold Buy Strong Buy

OLMA Price Target Upside V Benchmarks

TypeNameUpside
StockOlema Pharmaceuticals341.97%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-214
Avg Price Target-$25.00$38.00
Last Closing Price$6.41$6.41$6.41
Upside/Downside-290.02%492.82%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26291--12
Sep, 26291--12
Aug, 26291--12
Jul, 26291--12
Jun, 262101--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 14, 2026Laura PrendergastStifel Nicolaus$30.00$10.22193.54%368.02%
Aug 11, 2026Goldman Sachs$20.00$11.9467.50%212.01%
May 13, 2026Guggenheim$35.00$13.97150.54%446.02%
Mar 09, 2026Emily BodnarH.C. Wainwright$38.00$16.45131.00%492.82%
Feb 10, 2026Stifel Nicolaus$48.00$23.37105.39%648.83%
Jan 07, 2026Piper Sandler$40.00$25.0459.74%524.02%
Jan 07, 2026Michael YeeUBS$45.00$25.0479.71%602.03%
Dec 11, 2025Oppenheimer$48.00$31.6651.61%648.83%
Dec 11, 2025Goldman Sachs$38.00$30.6823.86%492.82%
Dec 11, 2025Emily BodnarH.C. Wainwright$45.00$32.2239.66%602.03%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 13, 2026CitigroupBuyBuyhold
Aug 11, 2026H.C. WainwrightBuyBuyhold
Aug 11, 2026CitigroupBuyBuyhold
May 22, 2026H.C. WainwrightBuyBuyhold
May 14, 2026CitigroupBuyBuyhold
Mar 26, 2026Wolfe ResearchPeer Performinitialise
Mar 09, 2026H.C. WainwrightBuyBuyhold
Mar 09, 2026Cowen & Co.BuyBuyhold
Mar 09, 2026OppenheimerOutperformOutperformhold
Jan 07, 2026Piper SandlerOverweightinitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.14$-2.20$-1.87---
Avg Forecast$-2.12$-2.30$-2.65$-3.12$-3.20$-1.94
High Forecast$-2.01$-2.20$-2.15$-2.47$-2.55$-1.94
Low Forecast$-2.27$-2.37$-3.29$-3.88$-3.84$-1.94
Surprise %0.94%-4.35%-29.43%---

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$4.50M$37.45M$154.40M
High Forecast---$4.50M$37.45M$154.40M
Low Forecast---$4.50M$37.45M$154.40M
Surprise %------

Net Income Forecast

$-180M $-161M $-142M $-123M $-104M $-85M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-96.66M$-129.47M$-162.45M---
Avg Forecast$-96.66M$-103.42M$-123.08M$-143.65M$-144.56M$-87.78M
High Forecast$-90.85M$-99.62M$-97.18M$-111.87M$-115.38M$-87.78M
Low Forecast$-102.94M$-107.21M$-148.98M$-175.44M$-173.75M$-87.78M
Surprise %-25.20%31.99%---

OLMA Forecast FAQ

Is Olema Pharmaceuticals stock a buy?

Olema Pharmaceuticals stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Olema Pharmaceuticals is a favorable investment for most analysts.

What is Olema Pharmaceuticals's price target?

Olema Pharmaceuticals's price target, set by 9 Wall Street analysts, averages $28.33 over the next 12 months. The price target range spans from $20 at the low end to $35 at the high end, suggesting a potential 341.97% change from the previous closing price of $6.41.

How does Olema Pharmaceuticals stock forecast compare to its benchmarks?

Olema Pharmaceuticals's stock forecast shows a 341.97% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Olema Pharmaceuticals over the past three months?

  • October 2026: 16.67% Strong Buy, 75.00% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 16.67% Strong Buy, 75.00% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 16.67% Strong Buy, 75.00% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.

What is Olema Pharmaceuticals’s EPS forecast?

Olema Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.12, marking a 66.84% increase from the reported $-1.87 in 2025. Estimates for the following years are $-3.2 in 2027, and $-1.94 in 2028.

What is Olema Pharmaceuticals’s revenue forecast?

Olema Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $4.5M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $37.45M, and $154.4M for 2028.

What is Olema Pharmaceuticals’s net income forecast?

Olema Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-144M, representing a -11.57% decrease from the reported $-162M in 2025. Projections indicate $-145M in 2027, and $-87.779M in 2028.